Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Daiichi Sankyo
US Army

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: RE38115

« Back to Dashboard

Summary for Patent: RE38115

Title: Dextromethorphan and an oxidase inhibitor for treating intractable conditions
Abstract:Methods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising administering dextromethorphan in combination with a therapeutically effective dosage of a debrisoquin hydroxylase inhibitor. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine.
Inventor(s): Smith; Richard Alan (La Jolla, CA), Licht; Jonathan M. (San Diego, CA)
Assignee: Center for Neurologic Study (La Jolla, CA)
Application Number:10/052,698
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

No matches for this query

Foreign Priority and PCT Information for Patent: RE38115

PCT Information
PCT FiledSeptember 22, 1994PCT Application Number:PCT/US94/10771
PCT Publication Date:March 28, 1996PCT Publication Number: WO96/09044

International Patent Family for Patent: RE38115

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia8071894► Subscribe
Germany69434794► Subscribe
European Patent Office0788359► Subscribe
European Patent Office1634597► Subscribe
Spain2268686► Subscribe
Japan4097285► Subscribe
JapanH10505864► Subscribe
World Intellectual Property Organization (WIPO)9609044► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus